Silver Book Fact

Cytokines in urine are associated with age-related macular degeneration (AMD) and could be developed as a biomarker and provide a practical tool for early detection

Guymer, Robyn H. Lingwui W. Tao, Jonathan K. Goh, Danny Liew, Olga Ischenko, Liubov D. Robman, KhinZaw Aung, Tania Cipriani, Melinda Cain, Andrea J. Richardson, Paul N. Baird, and Robyn Langham. Identification of Urine Biomarkers for AMD. Invest Opthalmol Vis Sci. 2011; 52(7): 4639-4644

Reference

Title
Identification of Urine Biomarkers for AMD
Publication
Invest Opthalmol Vis Sci
Publication Date
2011
Authors
Guymer, Robyn H. Lingwui W. Tao, Jonathan K. Goh, Danny Liew, Olga Ischenko, Liubov D. Robman, KhinZaw Aung, Tania Cipriani, Melinda Cain, Andrea J. Richardson, Paul N. Baird, and Robyn Langham
Volume & Issue
Volume 52, Issue 7
Pages
4639-4644

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.  
  • It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%,…  
  • Timely treatment and follow-up care can reduce the risk of blindness in individuals with proliferative retinopathy by 95%.  
  • After 54 weeks of receiving bevacizumab, wet age-realted macular degeneration (AMD) patients were more likely to gain at least 6 letters of contrast sensitivity than patikents recieving standard care–35.4% versus…  
  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.